Eli Lilly and Company (LLY)
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker last week abruptly announced that longtime CEO Lars Fruergaard Jorgensen is stepping down, as its obesity injection Wegovy loses ground to Eli Lilly's rival treatment, Zepbound.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 No-Brainer Stocks to Buy in May
Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the summer.
Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy
LLY's valuation remains highly attractive post-market overreaction, with the FY2025 bottom-line impact merely attributed to one-time acquired IPR&D expenses from ongoing M&A activities. Despite the tariff/ competition headwinds, its strategic capex investments within the US and intensified R&D efforts bolster its competitive advantage and growth prospects. While LLY's balance sheet may have temporarily deteriorated, we are not overly concerned, given the richer cash flow generation and stable leverage ratio thus far.
